Arcus Posts $9M Q3 Revenue, $694M Cash and Sets Multiple Casdatifan Milestones for Q4
RCUS is trading near its 52-week low of $17.43 (11% above the low).
Summary
Third-quarter revenue fell to $9 million from $26 million a year ago as Gilead collaboration work winds down, while net loss narrowed to $128 million from $135 million on lower R&D ($117 million vs $141 million) and G&A ($23 million vs $27 million), a loss of $1.00 per share. Cash and marketable securities stood at $694 million at September 30; management says that plus $288 million in gross October equity proceeds funds operations into 2029. Full-year 2026 revenue is guided to $70 million-$75 million. The pipeline calendar is the actionable part: PEAK-20, the first-line Phase 3 of casdatifan plus ipilimumab and nivolumab, starts in Q4 2026, PEAK-1 second-line enrollment completes within two to three months, a randomized late-line ARC-20 cohort begins in Q4 2026, and the PRISM-1 interim analysis for quemliclustat in pancreatic cancer is due in Q4 2026. Those readouts and trial starts are what will drive the stock from here, with the cash position removing near-term financing risk.
At the time of this announcement, RCUS was trading at $19.31 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $17.43 to $31.74. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.